Patents by Inventor Denis E. Ryono
Denis E. Ryono has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8614332Abstract: Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure is a heteroaryl ring; R4 is —(CH2)n—Z—(CH2)m—PO(OR7)(OR8), —(CH2)nZ—(CH2)m—PO(OR7)R9, —(CH2)n—Z—(CH2)m—OPO(OR7)R9, —(CH2)nZ—(CH2)m—OPO(R9)(R10), or —(CH2)nZ—(CH2)m—PO(R9)(R10); R5 and R6 are independently selected from H, alkyl and halogen; Y is R7(CH2)s or is absent; and X, n, Z, m, R4, R5, R6, R7, and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.Type: GrantFiled: February 15, 2012Date of Patent: December 24, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Denis E. Ryono, Peter T. W. Cheng, Scott A. Bolton, Sean Chen, Yan Shi, Wei Meng, Joseph A. Tino, Richard B. Sulsky
-
Patent number: 8273777Abstract: Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure where Q is and R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.Type: GrantFiled: August 30, 2010Date of Patent: September 25, 2012Assignee: Bristol-Meyer Squibb CompanyInventors: Yan Shi, Peter T. W. Cheng, Ying Wang, Denis E. Ryono
-
Patent number: 8263659Abstract: A method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described in the general formula I below is administered in a therapeutically effective amount:Type: GrantFiled: May 21, 2009Date of Patent: September 11, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Denis E. Ryono, Jon J. Hangeland, Todd J. Friends, Tamara Dejneka, Pratik Devasthale, Yolanda V. Caringal, Minsheng Zhang, Arthur M. P. Doweyko, Johan Malm, Andrei Sanin
-
Publication number: 20120142636Abstract: Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure is a heteroaryl ring; R4 is —(CH2)n—Z—(CH2)m—PO(OR7)(OR8), —(CH2)nZ—(CH2)m—PO(OR7)R9, —(CH2)n—Z—(CH2)m—OPO(OR7)R9, —(CH2)nZ—(CH2)m—OPO(R9)(R10), or —(CH2)nZ—(CH2)m—PO(R9)(R10); R5 and R6 are independently selected from H, alkyl and halogen; Y is R7(CH2)s or is absent; and X, n, Z, m, R4, R5, R6, R7, and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.Type: ApplicationFiled: February 15, 2012Publication date: June 7, 2012Inventors: Denis E. Ryono, Peter T.W. Cheng, Scott A. Bolton, Sean Chen, Yan Shi, Wei Meng, Joseph A. Tino, Richard B. Sulsky
-
Patent number: 8153677Abstract: Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R4 is —(CH2)n—Z—(CH2)m—PO(OR7)(OR8), —(CH2)nZ—(CH2)m—OPO(OR7)R9, —(CH2)nZ—(CH2)m—OPO(R9)(R10), or —(CH2)nZ—(CH2)m—PO(R9)(R10); R5 and R6 are independently selected from hydrogen, alkyl and halogen; Y is R7(CH2)s or is absent; and X, n, Z, m, R4, R5, R6, R7, and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.Type: GrantFiled: January 24, 2011Date of Patent: April 10, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Denis E. Ryono, Peter T. W. Cheng, Scott A. Bolton, Sean Chen, Yan Shi, Wei Meng, Joseph A. Tino, Richard B. Sulsky
-
Publication number: 20110118211Abstract: Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R4 is —(CH2)n—Z—(CH2)mPO(OR7)(OR8), —(CH2)nZ—(CH2)m—PO(OR7)R9, —(CH2)n—Z—(CH2)m—OPO(OR7)R9, —(CH2)nZ—(CH2)m—OPO(R9)(R10), or —(CH2)nZ—(CH2)m—PO(R9)(R10); R5 and R6 are independently selected from H, alkyl and halogen; Y is R7(CH2)s or is absent; and X, n, Z, m, R4, R5, R6, R7, and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.Type: ApplicationFiled: January 24, 2011Publication date: May 19, 2011Inventors: Denis E. Ryono, Peter T.W. Cheng, Scott A. Bolton, Sean Chen, Yan Shi, Wei Meng, Joseph A. Tino, Richard B. Sulsky
-
Patent number: 7910747Abstract: Pyrazoloamides are provided which are phosphonate and phosphinate glucokinase activators that are useful in treating diabetes and related diseases and have the structure wherein is a pyrazoyl ring; R4 is —(CH2)n—Z—(CH2)m—PO(OR7)(OR8), —(CH2)nZ—(CH2)m—PO(OR7)R9, or —(CH2)nZ—(CH2)m—PO(R9)(R10); R5 and R6 are independently selected from H, alkyl and halogen; Y is R3(CH2)s, wherein R3 is aryl , s is 0, X is a bond; and n, Z, m, R4, R5, R6, and R7 are as defined herein; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 28, 2007Date of Patent: March 22, 2011Assignee: Bristol-Myers Squibb CompanyInventors: Denis E. Ryono, Peter T. W. Cheng, Scott A. Bolton, Sean Chen, Yan Shi, Wei Meng, Joseph A. Tino
-
Publication number: 20100324071Abstract: Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure where Q is and R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.Type: ApplicationFiled: August 30, 2010Publication date: December 23, 2010Inventors: Yan Shi, Peter T. W. Cheng, Ying Wang, Denis E. Ryono
-
Publication number: 20100298276Abstract: Thyroid receptor ligands are provided which have the general formula I wherein: R1 is R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at least one of R2 and R3 is other than hydrogen; R4 is R5 and R6 are the same or different and are selected from hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl.Type: ApplicationFiled: May 21, 2009Publication date: November 25, 2010Inventors: Denis E. Ryono, Jon J. Hangeland, Todd J. Friends, Tamara Dejneka, Pratik Devasthale, Yolanda V. Caringal, Minsheng Zhang, Arthur M.P. Doweyko, Johan Malm, Andrei Sanin
-
Patent number: 7812048Abstract: Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure where Q is and R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.Type: GrantFiled: July 25, 2008Date of Patent: October 12, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Yan Shi, Peter T. W. Cheng, Ying Wang, Denis E. Ryono
-
Patent number: 7557143Abstract: Thyroid receptor ligands are provided which have the general formula I wherein: R1 is R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at least one of R2 and R3 is other than hydrogen; R4 is R5 and R6 are the same or different and are selected from hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl.Type: GrantFiled: April 15, 2004Date of Patent: July 7, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Denis E. Ryono, Jon J. Hangeland, Todd J. Friends, Tamara Dejneka, Pratik Devasthale, Yolanda V. Caringal, Minsheng Zhang, Arthur M. P. Doweyko, Johan Malm, Andrei Sanin
-
Publication number: 20090030046Abstract: Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure where Q is and R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.Type: ApplicationFiled: July 25, 2008Publication date: January 29, 2009Inventors: Yan Shi, Peter T.W. Cheng, Ying Wang, Denis E. Ryono
-
Patent number: 7342127Abstract: Novel thyroid receptor ligands are provided having the general formula I wherein X, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 are as defined herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolic dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.Type: GrantFiled: January 23, 2004Date of Patent: March 11, 2008Assignees: Bristol-Myers Squibb Company, Karo Bio ABInventors: William N. Washburn, Wei Meng, Denis E. Ryono, Bruce A. Ellsworth, Thomas Ericsson, Mahmoud Rahimi-Ghadim, Neeraj Garg, Johan Malm
-
Publication number: 20080009465Abstract: Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R4 is —(CH2)n-Z-(CH2)m—PO(OR7)(OR8), —(CH2)nZ-(CH2)m—PO(OR7)Rg, —(CH2)n-Z-(CH2)m—OPO(OR7)Rg, —(CH2)nZ—(CH2)m—OPO(R9)(R10), or —(CH2)nZ—(CH2)m—PO(R9)(R10); R5 and R6 are independently selected from H, alkyl and halogen; Y is R7(CH2)s or is absent; and X, n, Z, m, R4, R5, R6, R7, and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.Type: ApplicationFiled: June 28, 2007Publication date: January 10, 2008Inventors: Denis E. Ryono, Peter T.W. Cheng, Scott A. Bolton, Sean Chen, Yan Shi, Wei Meng, Joseph A. Tino, Hao Zhang, Richard B. Sulsky
-
Patent number: 7109164Abstract: New thyroid receptor ligands are provided which have the general formula in which: X is —O—, —S—, —CH2—, —CO—, or —NH—; Y is —(CH2)n— where n is an integer from 1 to 5, or cis- or trans-ethylene; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 6 carbons, at least one of R2 and R3 being other than hydrogen; R4 is hydrogen or lower alkyl; R5 is hydrogen or lower alkyl; R6 is carboxylic acid, or esters or prodrugs; R7 is hydrogen or an alkanoyl or an aroyl. In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.Type: GrantFiled: August 30, 2004Date of Patent: September 19, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Todd J. Friends, Denis E. Ryono, Minsheng Zhang
-
Patent number: 6800605Abstract: New thyroid receptor ligands are provided which have the general formula in which: X is —O—, —S—, —CH2—, —CO—, or —NH—; Y is —(CH2)n— where n is an integer from 1 to 5, or cis- or trans-ethylene; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 6 carbons, at least one of R2 and R3 being other than hydrogen; R4 is hydrogen or lower alkyl; R5 is hydrogen or lower alkyl; R6 is carboxylic acid, or esters or prodrugs; R7 is hydrogen or an alkanoyl or an aroyl. In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.Type: GrantFiled: January 16, 2001Date of Patent: October 5, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Todd J. Friends, Denis E. Ryono, Minsheng Zhang
-
Publication number: 20040180940Abstract: Novel thyroid receptor ligands are provided having the general formula I 1Type: ApplicationFiled: January 23, 2004Publication date: September 16, 2004Inventors: William N. Washburn, Wei Meng, Denis E. Ryono, Bruce A. Ellsworth, Thomas Ericsson, Mahmoud Rahimi-Ghadim, Neeraj Garg, Johan Malm
-
Patent number: 6395784Abstract: New thyroid receptor ligands are provided which have the general formula in which: X is —O—, —S—, —CH2—, —CO—, or —NH—; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 6 carbons, at least one of R2 and R3 being other than hydrogen; R4 is methyl, ethyl, n-propyl or trifluoromethyl; R5 is hydrogen or lower alkyl; R6 is carboxylic acid, or esters or prodrugs; R7 is hydrogen or an alkanoyl or an aroyl. In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.Type: GrantFiled: May 31, 2001Date of Patent: May 28, 2002Assignee: Bristol-Myers Squibb CompanyInventor: Denis E. Ryono
-
Patent number: 5770615Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof. These compounds are beta three adrenergic receptor agonists and are useful, therefore for example, in the treatment of diabetes, obesity and gastrointestinal diseases.Type: GrantFiled: March 28, 1997Date of Patent: June 23, 1998Assignee: Bristol-Myers Squibb CompanyInventors: Peter T. W. Cheng, Gregory S. Bisacchi, Ashvinikumar V. Gavai, Kathleen M. Poss, Denis E. Ryono, Philip M. Sher, Chong-qing Sun, William N. Washburn
-
Patent number: 5635504Abstract: Compounds of the formula ##STR1## wherein: ##STR2## A is are dual inhibitors of NEP and ACE. Compounds wherein A is ##STR3## are selective ACE inhibitors.Type: GrantFiled: March 1, 1996Date of Patent: June 3, 1997Assignee: Bristol-Myers Squibb Co.Inventors: Denis E. Ryono, Chong-Oing Sun